Rhythm Pharmaceuticals Inc is a biopharmaceutical company focused on developing treatments for rare neuroendocrine diseases. Its flagship product, IMCIVREE (setmelanotide), targets obesity caused by genetic deficiencies and is in advanced clinical trials. The company, founded in 2008 and based in Boston, Massachusetts, collaborates with several global partners to advance its research and bring new therapies to patients with unmet medical needs. Originally known as Rhythm Metabolic, Inc., it rebranded to its current name in 2015.
NVIDIA's blockbuster earnings sent shockwaves through tech on Thursday, but Wall Street analysts were busy reshaping the landscape elsewhere, issuing a flurry of upgrades, downgrades, and fresh initiations across energy, crypto infrastructure,…
Wall Street analysts are reshuffling their bets ahead of the busiest earnings week of the quarter, and the moves span everything from legacy automakers to crypto miners to space launch companies. Find…
Pre-Market Stock Futures: Futures are trading lower on Thursday, as Walmart’s forward outlook was disappointing. Risk-on was back on Wednesday, as the stock market, which is off to its worst start of…
